Eton Pharmaceuticals, Inc. (ETON): Cash & Equivalents
$25.94M
As of 2025-12-31
$26.84M
As of 2026-06-30
+16.7%
3-year compound annual growth
+4.0%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $25.94M | +73.7% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $14.94M | -30.2% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $21.39M | +31.2% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $16.30M | +13.2% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $14.41M | -32.4% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $21.30M | +76.5% | 2022-03-16, Balance as of period end |
| 2019-12-31 | $12.07M | -54.9% | 2021-03-16, Balance as of period end |
| 2018-12-31 | $26.73M | +103.2% | 2020-03-05, Balance as of period end |
| 2017-12-31 | $13.16M | n/a | 2019-03-25, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $25.94M | +73.7% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $261.34M | +4.2% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $230.91M | -2.6% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $12.67M | -66.7% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $246.96M | +124.5% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $41.32M | -18.7% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $128.51M | -17.8% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $120.86M | -27.5% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $122.52M | +29.2% |
Compare ETON, ADCT, ARCT, CTMX side by side · Screen every company in Pharmaceutical Preparations ↗